NEVVI Medicare utilization intelligence

← back

BOCCIA, RALPHM.D. NPI 1881663284 Clinician

Hematology-Oncology · BETHESDA, MD

Specialty Hematology-Oncology — from billed Medicare claims
Trained UNIVERSITY OF MINNESOTA MEDICAL SCHOOL — medical school, self-reported to CMS
In practice about 49 years since medical school (class of 1977, self-reported to CMS)
Location BETHESDA, MD · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 51 codes billed · 232,478 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
AMERICAN ONCOLOGY PARTNERS PA
2024–2026
AMERICAN ONCOLOGY PARTNERS OF MARYLAND, PA
2020–2023
RCCA MD LLC
2019–2020

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2023-01

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J1437 Injection, ferric derisomaltose, 10 mg
Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J0897 Injection, denosumab, 1 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
36415 Insertion of needle into vein for collection of blood sample
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96372 Injection of drug or substance under skin or into muscle
J1100 Injection, dexamethasone sodium phosphate, 1 mg
80053 Blood test, comprehensive group of blood chemicals
J2469 Injection, palonosetron hcl, 25 mcg
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
82728 Ferritin (blood protein) level
83540 Iron level
J1750 Injection, iron dextran, 50 mg
M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services
96375 Injection of additional new drug or substance into vein
96413 Administration of chemotherapy into vein, 1 hour or less
83615 Lactate dehydrogenase (enzyme) level
J3489 Injection, zoledronic acid, 1 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J1200 Injection, diphenhydramine hcl, up to 50 mg
82232 Beta-2 microglobulin (protein) level
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
82378 Carcinoembryonic antigen (cea) protein level
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
96415 Administration of chemotherapy into vein, each additional hour
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
85045 Red blood count, automated test
J7030 Infusion, normal saline solution , 1000 cc
96361 Infusion into a vein for hydration, each additional hour
99426 Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month
86300 Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3
96360 Infusion into a vein for hydration, 31-60 minutes
83735 Magnesium level
83550 Iron binding capacity
81002 Urinalysis, manual test
99195 Drawing of blood for a medical problem
84153 Psa (prostate specific antigen) measurement, total
J3490 Unclassified drugs
G0008 Administration of influenza virus vaccine
90653 Influenza vaccine, inactivated
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
84100 Phosphate level
38222 Biopsy and aspiration of bone marrow sample for diagnosis

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.